PMID- 32141538
OWN - NLM
STAT- MEDLINE
DCOM- 20210301
LR  - 20210301
IS  - 2284-0729 (Electronic)
IS  - 1128-3602 (Linking)
VI  - 24
IP  - 4
DP  - 2020 Feb
TI  - PKCalpha and Netrin-1/UNC5B positive feedback control in relation with chemical 
      therapy in bladder cancer.
PG  - 1712-1717
LID - 20346 [pii]
LID - 10.26355/eurrev_202002_20346 [doi]
AB  - OBJECTIVE: To explore the cisplatin medical tolerance mechanism affecting bladder 
      cancer cells. MATERIALS AND METHODS: Bladder cancer cells were treated with 
      protein kinase C alpha (PKCalpha) stimulation and inhibition agents. The 
      small-interfering RNA (siRNA) inhibitory technique was used to differentiate and 
      remove Netrin-1 from UNC5B. Cells treated by cisplatin were processed by the MIT 
      method to estimate cell death and growth rate. The Western blot method was 
      utilized to analyze PKCalpha, netrin-1, and UNC5B in bladder cancer cells, used in 
      the relative control sample. Co-immunoprecipitation was employed to analyze PKCalpha, 
      netrin-1, and UNC5B combination effects. RESULTS: PKCalpha high activity, netrin-1 
      high expression, and UNC5B with low expression can enhance bladder cancer cells 
      cisplatin medical tolerance. PKCalpha low activity, netrin-1 low expression, and 
      UNC5B with high expression can also enhance bladder cancer cells sensitivity to 
      chemical therapeutic treatments. PKCalpha high activity with enhanced netrin-1 
      reduced UNC5B expression, and also enhanced netrin-1/UNC5B combination. It 
      inhibits and/or deletes PKCalpha, Netrin-1 lower stream extracellular regulated 
      protein kinases (ERK) signal, deletes UNC5B, PKCalpha, and lowers stream (ERK) 
      signaling from activity. CONCLUSIONS: PKCalpha and netrin-1/UNC5B form a positive 
      feedback control loop in relation to the regulation of cisplatin in bladder 
      cancer cells.
FAU - Liu, J
AU  - Liu J
AD  - Department of Urology, The First Affiliated Hospital of China Medical University, 
      Shenyang, China. mskongchuize@sina.com.
FAU - Li, J
AU  - Li J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
RN  - 0 (Antineoplastic Agents)
RN  - 0 (NTN1 protein, human)
RN  - 0 (Naphthalenes)
RN  - 0 (Netrin Receptors)
RN  - 0 (UNC5B protein, human)
RN  - 158651-98-0 (Netrin-1)
RN  - EC 2.7.11.13 (PRKCA protein, human)
RN  - EC 2.7.11.13 (Protein Kinase C-alpha)
RN  - I271P23G24 (calphostin C)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - Antineoplastic Agents/*pharmacology
MH  - Cell Line, Tumor
MH  - Cisplatin/*pharmacology
MH  - Feedback, Physiological
MH  - Humans
MH  - Naphthalenes/pharmacology
MH  - Netrin Receptors/*metabolism
MH  - Netrin-1/*metabolism
MH  - Protein Kinase C-alpha/*metabolism
MH  - Urinary Bladder Neoplasms/drug therapy/*metabolism
EDAT- 2020/03/07 06:00
MHDA- 2021/03/02 06:00
CRDT- 2020/03/07 06:00
PHST- 2020/03/07 06:00 [entrez]
PHST- 2020/03/07 06:00 [pubmed]
PHST- 2021/03/02 06:00 [medline]
AID - 20346 [pii]
AID - 10.26355/eurrev_202002_20346 [doi]
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2020 Feb;24(4):1712-1717. doi: 
      10.26355/eurrev_202002_20346.